Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | AR | P10275 | 2/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5373770 | 0.84 | AR (0.55) | HPGDMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL183994 | 0.84 | LMNA (0.70) | HPGDLMNAMEN1KMT2AMRGPRX4 | |
| SCHEMBL391547 | 0.84 | MEN1 (0.71) | HPGDLMNAMEN1KMT2AMRGPRX4 | |
| SCHEMBL3132629 | 0.83 | LMNA (0.62) | HPGDLMNAMEN1KMT2AMRGPRX4 | |
| SCHEMBL4402201 | 0.83 | ALDH1A1 (0.44) | HPGDMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL31385500 | 0.83 | MRGPRX4 (0.63) | MRGPRX4MAOBNR4A2 | |
| SCHEMBL15163970 | 0.81 | HPGD (0.56) | HPGDLMNAMEN1KMT2AMRGPRX4 | |
| SCHEMBL17570969 | 0.81 | CA1 (0.48) | HPGDLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL3129603 | 0.80 | MEN1 (0.74) | HPGDLMNAMEN1KMT2AMRGPRX4 | |
| SCHEMBL29788280 | 0.80 | LMNA (0.65) | HPGDLMNAMEN1KMT2AMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118261-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-20080207616-A1 | Quinoxalines as B Baf Inhhibitors | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-20070259849-A1 | Azine-Carboxamides as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| EP-1828147-A1 | QUINOXALINES AS B-RAF INHIBITORS | AstraZeneca AB (SE) | 2007-09-05 | — | — | EP | disclosed |
| EP-1789399-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | AstraZeneca AB (SE) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006040568-A1 | QUINOXALINES AS B RAF INHIBITORS | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006024834-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118261-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | HPGD 1530/4885LMNA 2447/4885MEN1 1111/4885 |
| US-20070259849-A1 | Azine-Carboxamides as Anti-Cancer Agents | ARAF, BRAF, RAF1 | HPGD 3441/4885LMNA 4138/4885MEN1 486/4885 |
| US-20080207616-A1 | Quinoxalines as B Baf Inhhibitors | BRAF, NRAS, ARAF | HPGD 1324/4885LMNA 787/4885MEN1 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.